美国放射学会适宜性标准:睾丸癌分期与监测2021年更新
该指南由美国放射学会多学科专家小组制定,基于文献分析与RAND/UCLA适宜性方法及GRADE分级,针对睾丸精原细胞瘤和非精原细胞瘤的初始分期及IA和IB期按组织学亚型的监测,按影像 modality 和临床怀疑复发给出影像使用依据与推荐。
要点
- 睾丸癌分期与监测需整合临床、生化与影像,影像使用按肿瘤组织学和预后个体化定制。
- 指南按影像 modality 讨论初始分期依据,并针对IA和IB期按组织学亚型制定监测方案。
- 证据不足或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
核心结论
- 睾丸癌分期与监测的影像使用应基于肿瘤组织学和预后个体化定制,指南按影像 modality 及组织学亚型给出适宜性推荐。
研究设计与样本
- 美国放射学会适宜性标准由多学科专家小组每年审阅,制定与修订包括对同行评议期刊文献的广泛分析,并采用RAND/UCLA适宜性方法和GRADE对特定临床场景的影像与治疗操作适宜性进行评级。
诊断标准与关键数值
- 指南按影像 modality 讨论睾丸精原细胞瘤和非精原细胞瘤初始分期中影像使用的依据。
- 指南按组织学亚型讨论IA和IB期睾丸癌计划监测中影像使用的依据,并整合监测方案中对疾病复发的临床怀疑。
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
临床应用与阅片要点
- 初始分期和监测的影像选择应结合肿瘤组织学与预后因素个体化制定。
- 对IA和IB期睾丸癌,监测影像方案应按组织学亚型并整合临床对复发的怀疑来安排。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The staging and surveillance of testicular cancer is a complex topic, which integrates clinical, biochemical, and imaging components. The use of imaging for staging and surveillance of testicular cancer is individually tailored to each patient by considering tumor histology and prognosis. This document discusses the rationale for use of imaging by imaging modality during the initial staging of testicular seminoma and nonseminoma tumors and during the planned surveillance of stage IA and IB testicular cancer by histological subtype integrating clinical suspicion for disease recurrence in surveillance protocols. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
引用
- Schieda N, Oto A, Allen BC, et al. ACR Appropriateness Criteria® Staging and Surveillance of Testicular Cancer: 2021 Update. J Am Coll Radiol. 2022. PMID: 35550802. doi:10.1016/j.jacr.2022.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。